Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma

Inclusion Criteria: * Patients with endometrial cancer diagnosed on endometrial biopsy or dilatation and curettage. * Patients with invasive cervical cancer diagnosed on cervical biopsy or cone biopsy. * Patients with a performance status of 0, 1, 2, or 3 by the Gynecologic Oncology Group criteria (Appendix). * Patients with stage I to \~IIA invasive cervical cancer disease according to the International Federation of Gynecology and Obstetrics (FIGO) clinical staging criteria (Appendix). * Patients with clinical stage I endometrial cancer * Patients who will undergo surgery to include a hysterectomy, radical hysterectomy and/or radical trachelectomy and bilateral lymphadenectomy via laparotomy or laparoscopy * Patients who have signed an approved informed consent. Exclusion Criteria: * Patients with history of prior pelvic or para-aortic lymphadenectomy. * Patients with stage IIB-IV invasive cervical cancer by FIGO criteria. * Patients with recurrent endometrial or cervical cancer. * Patients with prior pelvic radiation. * Any patient with endometrial or cervical cancer treated with neoadjuvant chemotherapy and radiation therapy. * Patients with a performance score of 4 by the Gynecologic Oncology Group criteria or who are not good surgical candidates (Appendix). * Patients with grossly infected primary tumors. * Patients with known allergy to triphenyl-ethane compounds. * Patients with known deficiency of Glucose-G-Phosphate Dehydrogenase. * Patients with known Hemolytic Anemia from Pyruvate Kinase and G6PD Deficiencies. * Severe Renal Disease.